Synchronous and Metachronous Secondary Tumors of Bladder Cancer Patients
Journal Title: Üroonkoloji Bülteni - Year 2016, Vol 15, Issue 1
Abstract
The improvements in cancer treatment prolonged survival in patients. Despite this survival benefit, chemotherapies, radiotherapies or combination therapies, and continuing exposure to the same carcinogenic agents may lead to secondary cancers. Multiple primary neoplasm is described as multiple tumors in a single patient posing distinct individual malignant characteristics with definite exclusion of one tumor is the metastasis of the other. According to the time of onset, these are considered to be synchronous or metachronous tumors. While synchronous tumors often occur due to carcinogen exposure, metachronous tumors often develop after treatments such as radiotherapy. Although the cause and developmental mechanisms of multiple primary tumors are not clear, several factors including immune deficiency, genetic instability, increased use of systemic chemotherapy and radiotherapy, increased survival, elderliness, and smoking have been implicated. The two developmental hypotheses in development of multiple primary tumors appear as field cancerization and common clonal origin. Multiple primary tumors often involve respiratory, gastrointestinal, and genitourinary systems. Transitional cell carcinoma of the urinary bladder may also rise as part of synchronous or metachronous multiple tumors. We still lack large scale studies relevant to the treatment of multiple primary cancers. Close follow-up in primary malignant tumor patients is of extreme importance for the risk of secondary cancers.
Authors and Affiliations
Ayhan Dirim, Hakan Özkardeş, Eray Hasırcı
Keywords
Related Articles
- EP ID EP228270
- DOI 10.4274/uob.545
- Views 80
- Downloads 0
Immunohistochemical Study of Cyclooxygenase-2 Expression in Prostate Carcinoma: It’s Relation with Apoptosis and Angiogenesis
Objective: Prostate carcinoma (PC) is one of the most commonly diagnosed cancer types with significant rates of mortality and morbidity. The etiology of PC is not clear. Cytokine and mediators at the inflammatory pathway...
Histopathologic Parameters Accompanying by Incidental Prostate Cancer
Objective: It is known that incidental prostate cancer (IPCa) can be seen in a low possibility for patients who were performed transurethral resection of the prostate (TURP) due to bladder outlet obstruction and/ or pro...
Mycobacterium Brumae Extract Fractions with Potential Immunotherapeutic Activity for Bladder Cancer
Objective: Immunotherapy with intravesical Bacillus Calmette-Guérin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects. We...
Evaluation of Prostatic Artery Embolization Efficiency in Benign Prostatic Hyperplasia Patients with High Comorbidity
Objective: The purpose of this study was to evaluate efficacy outcomes following prostate artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) patients with high comorbidity. Materials and M...
A Rare Tumor: Prostate Neuroendocrine Carcinoma Case Report
Neuroendocrine prostate cancer is very rare disease with high mortality. It is one of the most commonly observed extrapulmonary small cell lung cancer types. In this case report we wanted to indicate how aggressive can n...